Search

Your search keyword '"Shahar, E."' showing total 686 results

Search Constraints

Start Over You searched for: Author "Shahar, E." Remove constraint Author: "Shahar, E."
686 results on '"Shahar, E."'

Search Results

1. Trends in mortality in people with HIV from 1999 to 2020: a multi-cohort collaboration

4. Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial

5. Risk for non-AIDS-defining and AIDS-defining cancer of early versus delayed initiation of antiretroviral therapy

6. Efficacité et sécurité à 24 mois (24M) de bictegravir/emtricitabine/ténofovir alafenamide (B/F/TAF) chez les personnes vivant avec le VIH (PVVIH) naïves (TN) et déjà traitées (TE) dans l'étude BICSTaR.

7. Risk for non-AIDS-defining and AIDS-defining cancer of early versus delayed initiation of antiretroviral therapy: A multinational prospective cohort study

8. Incidence of cancer and overall risk of mortality in individuals treated with raltegravir‐based and non‐raltegravir‐based combination antiretroviral therapy regimens

9. The extent of B‐cell activation and dysfunction preceding lymphoma development in HIV‐positive people†

10. Prevalence and Outcomes for Heavily Treatment-Experienced Individuals Living With Human Immunodeficiency Virus in a European Cohort

11. Apnea-hypopnea index: time to wake up

12. The association between hepatitis B virus infection and nonliver malignancies in persons living with HIV: results from the EuroSIDA study

13. Causal diagrams, the placebo effect, and the expectation effect

14. Causal diagrams and the cross-sectional study

15. Causal diagrams and the logic of matched case-control studies

17. HCV reinfection after HCV therapy among HIV/HCV-coinfected individuals in Europe

19. Gender differences in the use of cardiovascular interventions in HIV‐positive persons; the D:A:D Study

21. Sensitive testing of plasma HIV-1 RNA and Sanger sequencing of cellular HIV-1 DNA for the detection of drug resistance prior to starting first-line antiretroviral therapy with etravirine or efavirenz

22. Establishing a hepatitis C continuum of care among HIV/hepatitis C virus-coinfected individuals in EuroSIDA

23. Long‐term effectiveness of recommended boosted protease inhibitor‐based antiretroviral therapy in Europe

24. Causal diagrams and the logic of matched case-control studies [Corrigendum]

27. Lipid profiles for etravirine versus efavirenz in treatment-naive patients in the randomized, double-blind SENSE trial

28. Incidence of cancer and overall risk of mortality in individuals treated with raltegravir-based and non-raltegravir-based combination antiretroviral therapy regimens

30. Uptake and effectiveness of two-drug compared with three-drug antiretroviral regimens among HIV-positive individuals in Europe

31. Establishing a hepatitis C continuum of care among HIV/hepatitis C virus-coinfected individuals in EuroSIDA

34. Uptake and effectiveness of two-drug compared with three-drug antiretroviral regimens among HIV-positive individuals in Europe

37. Abacavir usage patterns and hypersensitivity reactions in the EuroSIDA cohort

41. Liver-related death among HIV/hepatitis C virus-co-infected individuals

48. Identification and characterization of HIV positive Ethiopian elite controllers in both Africa and Israel

50. Long-term effectiveness of unboosted atazanavir plus abacavir/lamivudine in subjects with virological suppression : A prospective cohort study

Catalog

Books, media, physical & digital resources